Our (e)Books and (e)Journals
IOS Press serves the information needs of scientific and medical communities worldwide. See what's new and browse our books and journals to learn more.
Browse by Subject
- Administrative Sciences
- Biochemistry, Medicine & Health
- Computer & Communication Sciences
- Environmental Sciences
- Geographic Information Science
IOS Press publishes books and journals (online and in print) in a broad range of scientific, technical and medical (STM) subject areas. Click on a subject above to see our titles.
NewsKeep me informed
March 24, 2017 - Amsterdam, NL – Parkinson’s disease (PD) is a progressive condition that often results in mobility impairments and can lead to decreased health-related quality of life (HRQL) and death. There is evidence that physical activity can delay decline in PD patients. In a study in the Journal of Parkinson’s Disease, researchers determined that that people who exercised regularly had significantly slower declines in HRQL and mobility over a two-year period.March 24, 2017
Journal of Parkinson’s Disease Celebrates Key Breakthroughs that Shaped PD Research over the Last 200 Years
March 22, 2017 - Amsterdam, The Netherlands - Marking the 200th anniversary of James Parkinson’s first published description of the disease that would come to bear his name, the Journal of Parkinson’s Disease is proud to publish Milestones in 200 Years of Parkinson’s Disease Research. This special issue features commentaries by luminaries in the field, who are responsible for some of the greatest advances in understanding and treating the disease since it was first characterized. The issue is openly available as a service to the Parkinson’s disease (PD) community.March 22, 2017
March 21, 2017 - Tel Aviv – A new Tel Aviv University study published in the Journal of Alzheimer's Disease finds that insulin resistance, caused in part by obesity and physical inactivity, is also linked to a more rapid decline in cognitive performance. According to the research, both diabetic and non-diabetic subjects with insulin resistance experienced accelerated cognitive decline in executive function and memory.March 21, 2017
March 17, 2017 -
A new study published in the Journal of Alzheimer's Disease shows Donepezil, a medication that is approved to treat people with Alzheimer’s disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation — the K-variant of butyrylcholinesterase, or BChE-K — donezpezil could accelerate cognitive decline.March 17, 2017